NovaMedica, a RUSNANO Portfolio Company, Launches an Innovative Pharmaceuticals Technology Center
Russian pharmaceutical company NovaMedica (a RUSNANO portfolio company) has launched a technological center to develop and put into pilot production innovative pharmaceuticals. It includes a complex of R&D laboratories and production sites with technological solutions, which are unique for the Russia pharmaceutical industry and one of the best in Europe. The key task of the Technological Center is to develop sophisticated oral pharmaceuticals of various pharmacotherapeutic groups including those to treat cardio-vascular and gastroenterological diseases, CNS diseases as well as to create new generation painkillers.
R&D laboratories of the Technological Center put into operation in late 2016 have already started working on five projects within the framework of NovaMedica’s own R&D program. Another four projects will be launched during this year. These are pharmaceuticals with innovative active agent delivery systems changing the bioavailability of drugs and allowing combining previously incompatible substances in one dose. Thanks to this, drugs that are being developed will have new application possibilities and will crucially surpass many existing analogues by their efficiency and safety.
Investments in the establishment of the Center located in the Moscow Technopolis amounted to 945 million RUR. The Center’s capabilities allow implementing 15-20 R&D projects on its venues and producing up to 40 million pieces of products per year. Innovative products will be patented and promoted both in Russia and in international markets. NovaMedica intends to develop scientific cooperation with leading Russian and foreign pharmaceutical companies, scientific and technological centers, universities and startups.
The development of its own portfolio of pharmaceuticals is an important but not the only task of NovaMedica’s technological center. The company plans to maintain partnerships and implement orders to develop pharmaceuticals for foreign and national companies. The global market of pharmacological developments is 8-10 billion USD per year, the Russian market amounts to about 1 billion RUR and has been growing 15-20% per year. By 2022, NovaMedica plans to acquire about 20% of the Russian market.
“Today we are launching an enterprise, which may be attributed to ‘big pharma’ without any exaggeration. Ultramodern equipment allowing research on a level previously unavailable in Russia, is installed here. Drugs that will be produced there are developed by largest world producers but the critical difference of NovaMedica is that we will not just produce generics, as many others do, out laboratory complex allows making our own R&D. I would like to highlight the role of the Moscow authorities. It would be much more difficult without their support and the infrastructure complex created in Technopolis,” Anatoly Chubais, Chairman of the Management Board of MC RUSNANO, said.
“The establishment of the Technological Center will significantly accelerate the development and release of national innovative pharmaceutical to the market. However, in order to saturate the Russian market with drugs urgently needed by Russian patients, we need to work in all areas. Today we have launched the Technological Center in Moscow and in May—within the framework of NovaMedica’s partnership with Pfizer—we will start building an GMP plant to produce sterile injection drugs in the Kaluga region. More than 30 vital and essential pharmaceuticals to treat severe bacterial and fungal infections, inflammatory and cancer diseases will be localized at the plant,” Leonid Melaved, a member of NovaMedica’s Board of Directors, noted.
“The launch of the modern Technological Center of NovaMedica is an important step to develop the Russian R&D industry, which on the one hand is an indicator of the state social and economic development and on the other hand is an interlink of import substitution in the high-tech industry of our country,” Kirill Kaem, Vice President of the Skolkovo Fund and Managing Director of the Biomedical Technology Cluster, commented.
RUSNANO Joint-Stock Company was founded in March 2011 through reorganization of state corporation Russian Corporation of Nanotechnologies. JSC RUSNANO contributes to implementation of the state policy on the development of the nanotechnology industry by investing directly and through investment funds of nanotechnology in financially effective high-technology projects providing the development of new production facilities in the Russian Federation. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. 100 percent of RUSNANO’s shares are state owned. Thanks to RUSNANO’s investments, there are currently 103 factories and R&D Centers opened in 37 regions in Russia. JSC RUSNANO has profit for the last 5 years.
Management of assets of RUSNANO JSC is carried out by Limited Liability Company established in December 2013, RUSNANO Management Company. Anatoly Chubais is the Chairman of its Executive Board.
Work to establish nanotechnology infrastructure and carry out educational programs is fulfilled by RUSNANO’s Fund for Infrastructure and Educational Programs, which was also established during the reorganization of the Russian Corporation of Nanotechnologies.
* * *
The creation and development of the Technological Center is performed by NovaMedica Innotech LLC, a research and development division of NovaMedica, established to develop new pharmaceuticals and transfer intellectual property rights (100% subsidiary of NovaMedica LLC, a participant of the Skolkovo project starting from July, 2013).